Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically proven in operable advanced gastric adenocarcinoma (including adenocarcinoma of the gastrooesophageal junction) or relapse gastric adenocarcinoma~* Subjects must be able to take orally~* Measurable lesion and/or non-measurable lesion defined by RECIST~* ECOG performance status ≦ 1~* Hgb ≧ 8g/dL, WBC 4000-12000/mm3, platelets ≧ 100,000/mm3~* Creatine ≦ upper normal limit (UNL)~* Total bilirubin ≦ 1.5 X UNL~* AST, ALT and ALP ≦ 2.5 x UNL~* No prior chemotherapy~* Life expectancy estimated than 3 months~* Written informed consent~Exclusion Criteria:~* Active double cancer~* Gastrointestinal bleeding~* Excessive amounts of ascites require drainage~* Known brain metastases~* Symptomatic peripheral neuropathy ≧ garde 2. by NCI-CTCAE ver.3.0~* Pulmonary fibrosis, Intestinal pneumonitis~* History of hypersensitivity to fluoropyrimidines, docetaxel or medications formulated with polysorbate 80~* Any previous chemotherapy or radiotherapy for AGC~* Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant~* Treatment with any investigational product during the last 4 weeks prior to study entry~* Definite contraindications for the use of corticosteroids~* Any subject judged by the investigator to be unfit for any reason to participate in the study

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 79 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Docetaxel + S-1
- 2 (Type: ACTIVE_COMPARATOR): S-1

Based on this trial design, predict the completion outcome and termination type (if applicable).